SYH2068 vs Zerlasiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: LPA gene / apolipoprotein(a) mRNA · full Atherosclerotic Cardiovascular Disease pipeline

SYH2068

Developed by CSPC Pharmaceutical Group

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2028 · NCT07640217 (registry estimate)

No aligned efficacy figure on record for this race.

Zerlasiran

Developed by Silence Therapeutics

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT05537571 · Phase 2 · completed

The trial randomized participants to three zerlasiran regimens or placebo and masked both participants and investigators, with 180 participants enrolled. The primary endpoint was met for all active regimens, with statistically significant reductions in lipoprotein(a) versus pooled placebo; however, because the primary endpoint was a surrogate biomarker rather than a clinical outcome, this evidence is rated moderate.

Reported efficacy

Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36: Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36 (Week 36): SLN360 300 mg Q16W -80.5% (Standard Error 1.99) | SLN360 300 mg Q24W -79.1% (Standard Error 1.94) | SLN360 450 mg Q24W -83.3% (Standard Error 1.92) vs Pooled Placebo 2.3% (Standard Error 1.88) (met)

Result source: NCT05537571

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSYH2068Zerlasiran
LDL-C, % change—Not reported-14.7% vs 9.3%−24 vs placebo450 mg Q24W · wk 60 · n 45NCT05537571
8 other results
  • -17% vs 8.9% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -15.5% vs 9.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -19.3% vs 9.3% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -16.8% vs 9.3% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -20.9% vs 8.9% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -18.5% vs 8.9% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -22.3% vs 9.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -20.1% vs 9.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported-16.4% vs -3.8%−12.6 vs placebo450 mg Q24W · wk 60 · n 45NCT05537571
8 other results
  • -18% vs -4% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -18.6% vs -3.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -15% vs -3.8% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -10.9% vs -3.8% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -16.4% vs -4% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -12.6% vs -4% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -16.9% vs -3.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -13.5% vs -3.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571
Lp(a), % change—Not reported-83.3% vs 2.3%−85.6 vs placebo450 mg Q24W · wk 36 · n 45NCT05537571
8 other results
  • -80.5% vs 2.3% 300 mg Q16W · wk 36 · n 42 · Phase 2 · primary NCT05537571
  • -79.1% vs 2.3% 300 mg Q24W · wk 36 · n 44 · Phase 2 · primary NCT05537571
  • -76% vs 1.1% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -81.5% vs 1.5% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -78% vs 1.1% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -70.7% vs 1.1% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -81.6% vs 1.5% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -77.2% vs 1.5% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

SYH2068
—Not reported
Zerlasiran
-14.7% vs 9.3%−24 vs placebo450 mg Q24W · wk 60 · n 45NCT05537571
8 other results
  • -17% vs 8.9% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -15.5% vs 9.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -19.3% vs 9.3% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -16.8% vs 9.3% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -20.9% vs 8.9% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -18.5% vs 8.9% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -22.3% vs 9.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -20.1% vs 9.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571

Non-HDL-C, % change

SYH2068
—Not reported
Zerlasiran
—Not reported

ApoB, % change

SYH2068
—Not reported
Zerlasiran
-16.4% vs -3.8%−12.6 vs placebo450 mg Q24W · wk 60 · n 45NCT05537571
8 other results
  • -18% vs -4% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -18.6% vs -3.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -15% vs -3.8% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -10.9% vs -3.8% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -16.4% vs -4% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -12.6% vs -4% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -16.9% vs -3.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -13.5% vs -3.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571

Lp(a), % change

SYH2068
—Not reported
Zerlasiran
-83.3% vs 2.3%−85.6 vs placebo450 mg Q24W · wk 36 · n 45NCT05537571
8 other results
  • -80.5% vs 2.3% 300 mg Q16W · wk 36 · n 42 · Phase 2 · primary NCT05537571
  • -79.1% vs 2.3% 300 mg Q24W · wk 36 · n 44 · Phase 2 · primary NCT05537571
  • -76% vs 1.1% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -81.5% vs 1.5% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -78% vs 1.1% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -70.7% vs 1.1% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -81.6% vs 1.5% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -77.2% vs 1.5% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571

3-point MACE (% with event)

SYH2068
—Not reported
Zerlasiran
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SYH2068: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. SYH2068: 0 of 4 rows · Zerlasiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricZerlasiran
Dropout rate
2.2%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
11.4%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
2.3%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Discontinued due to AEs
0%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
4.5%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
0%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Serious AEs
11.1%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
14.3%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
4.5%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Most frequent reported AEs
450 mg Q24W
injection site reaction 82.2% (placebo 8.7%)
influenza-like illness 15.6% (placebo 0%)
myalgia 15.6% (placebo 4.3%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
300 mg Q16W
injection site reaction 83.3% (placebo 8.7%)
malaise 14.3% (placebo 0%)
upper respiratory tract infection 14.3% (placebo 4.3%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
300 mg Q24W
injection site reaction 81.8% (placebo 8.7%)
upper respiratory tract infection 15.9% (placebo 4.3%)
covid-19 13.6% (placebo 13%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zerlasiran

Lp(a -83.3% (n=45) vs 2.3% (n=47) placebo @ 36wk450 mg Q24W
percent change · % of baseline
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 8 more results
-81.5% (n=45) vs 1.5% (n=47) placebo @ 48wk450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-76% (n=45) vs 1.1% (n=47) placebo @ 60wk450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-80.5% (n=42) vs 2.3% (n=47) placebo @ 36wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-79.1% (n=44) vs 2.3% (n=47) placebo @ 36wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-81.6% (n=42) vs 1.5% (n=47) placebo @ 48wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-77.2% (n=44) vs 1.5% (n=47) placebo @ 48wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-78% (n=42) vs 1.1% (n=47) placebo @ 60wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-70.7% (n=44) vs 1.1% (n=47) placebo @ 60wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Apo B -18.6% (n=45) vs -3.6% (n=47) placebo @ 36wk450 mg Q24W
percent change · % of baseline
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 8 more results
-18% (n=45) vs -4% (n=47) placebo @ 48wk450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-16.4% (n=45) vs -3.8% (n=47) placebo @ 60wk450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-16.9% (n=42) vs -3.6% (n=47) placebo @ 36wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-13.5% (n=44) vs -3.6% (n=47) placebo @ 36wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-16.4% (n=42) vs -4% (n=47) placebo @ 48wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-12.6% (n=44) vs -4% (n=47) placebo @ 48wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-15% (n=42) vs -3.8% (n=47) placebo @ 60wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-10.9% (n=44) vs -3.8% (n=47) placebo @ 60wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
LDL-C -15.5% (n=45) vs 9.6% (n=47) placebo @ 36wk450 mg Q24W
percent change · % of baseline
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 8 more results
-17% (n=45) vs 8.9% (n=47) placebo @ 48wk450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-14.7% (n=45) vs 9.3% (n=47) placebo @ 60wk450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-22.3% (n=42) vs 9.6% (n=47) placebo @ 36wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-20.1% (n=44) vs 9.6% (n=47) placebo @ 36wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-20.9% (n=42) vs 8.9% (n=47) placebo @ 48wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-18.5% (n=44) vs 8.9% (n=47) placebo @ 48wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-19.3% (n=42) vs 9.3% (n=47) placebo @ 60wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-16.8% (n=44) vs 9.3% (n=47) placebo @ 60wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SYH2068's landscape · Zerlasiran's landscape